LGND
Ligand Pharmaceuticals Inc.About LGND
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
Company
- Headquarters
- San Diego, CA
- Employees
- 47 (2026)
- Listed
- Nov 25, 1994
- Exchange
- Nasdaq
- Website
- ligand.com
- SEC industry
- Pharmaceutical Preparations
- Cylvex sector
- Health Care · Pharmaceuticals
Pharmaceuticals
- Market cap #44 of 429
- P/B #73 of 396
Ranked highest first among stocks Cylvex covers.
- LLYEli Lilly and Company$1.29T+5.11%
- JNJJohnson & Johnson$677.3B+2.24%
- ABBVAbbVie Inc$518.7B+0.95%
- MRKMerck & Co Inc$371.1B+2.79%
- NVSNovartis AG$309.9B+1.19%
Financial summary
Related companies
About
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
From company filings and market data · Not investment advice
Price data
52W range and average volume from daily bars (unadjusted, last 252 sessions).
Financials
Consensus estimates
The information provided is for educational purposes only and does not constitute investment advice. Past performance does not guarantee future results.